But, the latest research shows that STAT6 is an almost completely specific and highly sensitive immunohistochemical marker for SFT.[29,30] In addition, molecular genetics identified the fusion of NAB2-STAT6 as the latest molecular marker, with high sensitivity and specificity.[1,27] According to morphology, histological, and immunohistochemistry results, it is clear that our patients meet the diagnostic criteria for atypical/malignant SFT of the pancreas with spleen vein invasion. The gene discussed is NAB2; the disease is solitary fibrous tumor.